This distinction provides a more useful scientific framework than describing the compounds as a peptide stack. Research comparing these signalling systems can examine receptor activation, intracellular second messengers, pituitary responses, receptor expression and the timing of hormone secretion. The distinction is particularly important because studies have identified interactions between GHRH and GHS signalling while also demonstrating that the two pathways are not simply interchangeable.
Sermorelin and the GHRH Receptor
Sermorelin is a synthetic peptide which consists of the first 29 amino acid residues of human growth hormone-releasing hormone. Research into GHRH(1-29)-NH2 and other analogues has been carried out in order to examine the structural features that are involved in the activation of the GHRH receptor. Studies on structure-activity have looked at the effect of modifying the amino acid sequence on receptor activity and on the biological response.
The GHRH receptor is a member of the class B G protein-coupled receptor family and is notably found in pituitary somatotroph cells. When it is activated, it mainly causes adenylyl cyclase to be stimulated with a consequent rise in intracellular cyclic AMP. Further signalling may include the activation of protein kinase A and transcriptional mechanisms related to somatotroph function.
The GHRH receptor therefore represents an important target for research into the way that GHRH-related peptides regulate signalling in the pituitary.
GHRP-2 and GHS-R Signalling
GHRP-2 is a member of the growth hormone-releasing peptide family. Unlike Sermorelin, its main experimental target is the growth hormone secretagogue receptor, which is generally known as GHS-R.
GHS-R is a G protein-coupled receptor that takes part in the signalling action of growth hormone secretagogues and the endogenous peptide ghrelin; experimental research has found a number of intracellular signalling components associated with the activation of GHS-R, such as phospholipase C, intracellular calcium, protein kinase C and other subsequent pathways.
Research carried out on pituitary cells has likewise shown that GHRP-2 is able to stimulate the release of growth hormone by means that are different from those triggered by GHRH. In experiments on rats' pituitary glands, the activity of GHRP-2 was mainly linked to the GHS receptor system and did not require normal signalling through GHRH receptors.
Two Peptides, Two Primary Receptor Systems
The key difference between Sermorelin and GHRP-2 lies in the receptor involved.
Primary Sermorelin research target
The receptor for growth hormone-releasing hormone, which is a class B G protein-coupled receptor mainly linked to adenylyl cyclase and cAMP signalling in the pituitary somatotrophs.
Primary GHRP-2 research target
GHS-R is a particular GPCR that is linked to growth hormone secretagogue and ghrelin signalling. Experimental systems have identified calcium mobilisation, phospholipase C, protein kinase C and other signalling mechanisms.
Since the receptor systems are different, the two compounds should not be regarded as identical experimental stimuli.
How GHRH and GHS Signalling Can Interact
Even though the receptors are different, research shows that their signalling pathways are able to interact.
A cellular study using systems expressing both GHRH and GHS receptors found that GHRH receptor activation increased cAMP, while activation of the GHS receptor potentiated the cAMP response generated by GHRH receptor activation. This suggests that receptor-level interaction can occur without the two receptors becoming the same signalling system.
Other experimental work has examined GHRH and GHRP-2 together in pituitary cells. In ovine somatotrope cultures, both peptides altered growth hormone-related gene expression and secretion, while also affecting expression of GHRH receptor, GHS receptor and somatostatin receptor transcripts.
These findings are useful for experimental design because a combined response does not necessarily demonstrate that the peptides share a receptor. It may instead reflect signalling convergence or receptor-level crosstalk.
GHRP-2 Does Not Simply Depend on GHRH Receptor Activation
The relationship between GHRP-2 and GHRH signalling has been looked at in a number of experimental systems.
A study looked at the responses to GHRP-2 in people who had mutations affecting the GHRH receptor; in these individuals a measurable growth hormone response to GHRP-2 was still obtained, the response however being considerably different from that seen in the control subjects. The results provided evidence for the presence of GHRP-2 activity which does not need an intact GHRH receptor pathway.
Similar experiments have yielded comparable results. When the expression of GHS-R was suppressed, that of growth hormone secretion induced by GHRP-2 was reduced, but suppressing the expression of the GHRH receptor did not eliminate the response to GHRP-2 under the experimental conditions employed.
It is important to make this distinction when interpreting research which looks at Sermorelin and GHRP-2 together, since the combined effect should be examined at both the receptor and signalling level and not be credited to a single common mechanism.
Intracellular Signalling as a Research Endpoint
Receptor binding alone does not describe the complete biological response to a peptide.
For Sermorelin and related GHRH analogues, cAMP generation is an established signalling endpoint because GHRH receptor activation is closely associated with adenylyl cyclase activity. Changes in downstream signalling can subsequently be evaluated through protein kinase activity, transcriptional responses and growth hormone secretion.
GHRP-2 research can involve a different set of endpoints. Studies have examined phospholipase C activity, intracellular calcium, protein kinase C and interactions between GHS-R and cAMP-related signalling.
As a result, an experiment that compares the two peptides will yield more useful information if several signalling endpoints are measured rather than depending only on the final hormone concentration.
Receptor Expression Can Change During an Experiment
Another factor that can affect interpretation is the level of receptor expression.
Studies carried out on cultured pituitary cells have looked at the effect of exposure to GHRH and GHRP-2 on the expression of messenger RNA for the GHRH receptor and the GHS receptor. Research has found that changes in receptor expression occur as a result of exposure to these signalling molecules, which shows that the amount of receptors might not stay the same during the entire experimental period.
This is something that should be considered when the short-duration experiments are compared with the longer-duration ones. A response seen following a brief exposure might indicate acute receptor signalling, while prolonged exposure can lead to changes in receptor expression and in cellular responsiveness.
The experimental duration should therefore be regarded as a significant variable not a small methodological detail.
Temporal Response and Experimental Sampling
The secretion of growth hormone is naturally dynamic, so a single measurement won't be sufficient to describe the response caused by a peptide.
Studies on GHRH-related peptides have employed repeated hormone measurements in order to identify changes over time; the same considerations hold true in the case of studies on GHRP-2, especially when the researchers are looking at the peak response, the duration of the response or changes in the concentrations of downstream hormones.
When carrying out comparative experiments, the sampling intervals should be determined before the study starts. The timing of receptor activation, together with that of intracellular signalling and hormone release, may not be the same, so measurements taken at different stages may refer to different biological processes.
That is one of the reasons why the results from individual studies cannot always be compared directly even when the same peptide is being examined.
Experimental Models Used in Sermorelin and GHRP-2 Research
Sermorelin and GHRP-2 have been studied by means of a number of experimental methods.
Using pituitary cell cultures, researchers are able to investigate receptor signalling, the role of intracellular messengers, gene expression and secretory responses under controlled conditions. Studies have employed ovine and rodent somatotrope models in order to examine the interactions between GHRH and GHRP signalling.
Receptor-expression systems offer a further stage for investigation. By using cells which have been engineered to express GHRH and GHS receptors it is possible to separate out receptor-specific signalling and examine possible interactions between pathways.
Research carried out by humans has also looked into the endocrine response to GHRH-related peptides and GHRP-2. Yet it is not correct to regard the findings from studies of humans, animal models and isolated cells as being the same since receptor expression, peptide metabolism and endocrine regulation can vary between the different systems.
GHRP-2 and Additional Pituitary Signalling
An important limitation in GHRP-2 research is that its biological activity is not necessarily restricted to growth hormone.
Experimental studies have reported GHRP-2-associated ACTH responses. Research in mouse pituitary cells found that GHRP-2 could stimulate ACTH secretion and that both PKA- and PKC-related pathways contributed to the response under the experimental conditions studied.
Research carried out by humans has also looked at the responses of ACTH and cortisol after exposure to GHRP-2. The results show that a study which concentrates only on growth hormone may fail to take into account other endocrine endpoints that are relevant to interpretation.
It does not prove any therapeutic effect or lead to clinical use; it only shows how important it is to measure appropriate controls and the relevant endocrine markers when researching GHS-R ligands.
Peptide Structure Matters in Comparative Research
Sermorelin and GHRP-2 are very different in terms of their peptide structure.
Sermorelin is a peptide analogue derived from growth hormone-releasing hormone and consists of 29 amino acid residues, whereas GHRP-2 is a considerably shorter growth hormone-releasing peptide. Research into structure-activity relationships shows that relatively small modifications to the peptide sequence or its conformation can lead to changes in receptor interaction and biological activity.
The identity of the material used in laboratory research should therefore be determined on its own, without referring to the marketing description, since the sequence, molecular mass, purity and analytical data all have a role in confirming the material under investigation.
It is especially relevant when one compares published literature with research materials that carry commercial labels.
What can be measured in comparative research?
A study involving Sermorelin and GHRP-2 which is well controlled can look at a number of different levels of biology.
At the level of the receptor, researchers can examine either the expression or the activation of GHRH receptors and GHS receptors.
At the intracellular level, studies can examine cAMP, calcium mobilisation, phospholipase C, protein kinase activity and related signalling pathways.
At the transcriptional level, researchers can measure changes in receptor, signalling and pituitary transcription factor expression.
At the endocrine level, growth hormone can be measured alongside other relevant pituitary hormones where the experimental question requires it.
The endpoint that should be used will vary according to the research model; for example, a receptor-binding experiment, a pituitary-cell experiment and a whole-organism endocrine study each address different questions and therefore cannot be regarded as interchangeable evidence.
Limitations of Current Research
A large amount of the existing mechanistic research into GHRH and GHRP signalling has been carried out using older animal, cell-based and receptor-expression studies. Although these experiments are still useful for gaining an understanding of receptor biology, the results obtained from them should be interpreted in the light of the model employed.
Species differences are of great importance in GHS-R research; previous literature has shown that there are differences in signalling responses among experimental species, which indicates that receptor pharmacology cannot always be directly transferred from one model to another.
A further limitation concerns the difference between acute signalling and longer-term receptor regulation; a peptide may give rise to one pattern of signalling when there is a short exposure but yet cause a change in receptor expression or in cellular responsiveness with prolonged exposure.
That alone does not mean that a therapeutic result has been achieved, and experimental hormonal responses must be kept separate from any assertions regarding tissue repair, recovery, performance or the treatment of disease.
Why Sermorelin and GHRP-2 Are Useful for Comparative Research
Sermorelin and GHRP-2 provide a useful model for examining how different peptide ligands can influence the same endocrine system through distinct receptor pathways.
Sermorelin research centres on GHRH receptor signalling and its relationship with cAMP-dependent pituitary pathways. GHRP-2 research centres on GHS-R signalling and associated intracellular pathways involving calcium, phospholipase C and protein kinase activity.
It is therefore possible for research that looks at both systems to study receptor specificity, pathway interaction, temporal signalling, receptor regulation and endocrine response without considering the compounds as interchangeable materials.
What is important from a scientific point of view is to understand the differences rather than attributing a common result to the compounds.
Research Use Only
The information given on this page is for use in scientific and educational research only and the peptides referred to here are not being offered as medicines, treatments or products for human consumption.
This material is meant to help with an understanding of peptide structure, receptor pharmacology, signalling pathways, and existing research using experimental models. It does not include any information regarding dosing, administration protocols, or therapeutic recommendations.
Before starting any laboratory work, researchers should look over the relevant product documentation, the analytical data and the batch-specific certificates.
If you are a researcher looking into peptide structure, receptor biology and experimental signalling systems, you should look over the available materials.
View research materialsFAQs
References
- Grossman A, Savage MO, Lytras N, Preece MA, Sueiras-Diaz J, Coy DH, Rees LH, Besser GM. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol (Oxf). 1984 Sep;21(3):321-30. doi: 10.1111/j.1365-2265.1984.tb03477.x. PubMed ↗
- Mayo KE, Miller T, DeAlmeida V, Godfrey P, Zheng J, Cunha SR. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog Horm Res. 2000;55:237-66; discussion 266-7. PubMed ↗
- Smith RG, Leonard R, Bailey AR, Palyha O, Feighner S, Tan C, Mckee KK, Pong SS, Griffin P, Howard A. Growth hormone secretagogue receptor family members and ligands. Endocrine. 2001 Feb;14(1):9-14. doi: 10.1385/ENDO:14:1:009. PubMed ↗
- Smith RG, Leonard R, Bailey AR, Palyha O, Feighner S, Tan C, Mckee KK, Pong SS, Griffin P, Howard A. Growth hormone secretagogue receptor family members and ligands. Endocrine. 2001 Feb;14(1):9-14. doi: 10.1385/ENDO:14:1:009. PubMed ↗
- Roh SG, Chen C, Choi KC, Shrestha Y, Sasaki S. Is GHRH receptor essential to GHRP-2-induced GH secretion in primary cultured rat pituitary cells? Endocrinology. 2002 May;143(5):1964-7. doi: 10.1210/endo.143.5.8893. PubMed ↗
- Yan M, Hernandez M, Xu R, Chen C. Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells. Eur J Endocrinol. 2004 Feb;150(2):235-42. doi: 10.1530/eje.0.1500235. PubMed ↗
- Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002 Dec;143(12):4570-82. doi: 10.1210/en.2002-220670. PubMed ↗
- Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo SP, Abelin N, Levine MA, Bowers CY, Souza AH, Pereira RM, Santos NL, Salvatori R. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. J Clin Endocrinol Metab. 2001 Jul;86(7):3279-83. doi: 10.1210/jcem.86.7.7694. PubMed ↗
- Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies. J Med Chem. 1998 Feb 26;41(5):717-27. doi: 10.1021/jm970618s. PubMed ↗
